REPL: Replimune to resubmit RP1 BLA after FDA agrees to prioritized review

AI Summary

Replimune said it will resubmit the BLA for RP1 (vusolimogene oderparepvec) plus nivolumab for advanced melanoma in the coming days after collaborative discussions with the FDA. The agency told the company it will treat the resubmission as urgent and prioritize review; the application is supported by IGNYTE trial data in patients who progressed on anti‑PD‑1 therapy, a population with limited treatment options.

Positives

Company will file RP1 BLA resubmission in coming days
FDA indicated it will treat the resubmission as urgent and prioritize review
BLA is supported by IGNYTE data in patients who progressed on prior anti‑PD‑1 therapy

Negatives

Resubmission is not an approval — final regulatory outcome remains uncertain
No new efficacy or safety details disclosed in this announcement
FDA could still identify deficiencies during its prioritized review